← Saniona AB (SANION.ST) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Saniona AB (SANION.ST)
Pharmaceutical Preparations · market cap $130M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Saniona AB (SANION.ST) is a Swedish pharmaceutical company with 43 employees and a market cap of approximately $170M, focused on rare neurological and metabolic disorders. Its lead and sole disclosed pipeline asset is a tesofensine/metoprolol combination in Phase 2 development for Prader-Willi Syndrome (PWS) in patients with a confirmed genetic diagnosis. No upcoming catalysts are currently calendared, and key financial details including cash, runway, and dilution metrics are not disclosed in the available facts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NS2359 | Phase 2 | Cocaine Use Disorder |
| Tesofensine/Metoprolol | Phase 2 | Type 2 Diabetes Mellitus |
Price & technical context
3-month
-25.0%
6-month
-38.2%
12-month
-18.0%
52-wk range
$9.45–$27.50
vs 50-day MA
-17.6%
vs 200-day MA
-39.3%
Realized vol
56.5%
Max drawdown
-65.6%
Daily closes through 2026-10-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SANION.ST (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.